Nasdaq · CIK 0001472012
IMNM Immunome Inc.
Insider trading from SEC Form 4. Last filing 27 d ago. Close $19.55 on Oct 9, 2026, +40% from the 52-week low and -34% from the high.
Last 90 days
Net insider value
-$334k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$334k by 1 insider
Insiders on file
7
with a Form 4 at this company
Price and insider trades, last year
IMNMOct 9, 2026 · close 19.55
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Immunome Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Jack Higgins Chief Scientific Officer sell | $334k 13,200 shares | -17% | - | |
| 37Weak | Jean Jacques Bienaime director buy | $47k 5,000 shares | +16% | +67% from low-42% from high | |
| 48Moderate | Jean Jacques Bienaime director buy | $61k 7,800 shares | +33% | - | |
| 76Notable | Clay B Siegall President and CEO buy | $999k 137,100 shares | +20% | - | |
| 43Moderate | Jean Jacques Bienaime director buy | $57k 7,000 shares | +42% | - | |
| 50Moderate | Philip Tsai Chief Technology Officer buy | $104k 12,300 shares | +59% | - | |
| 61Notable | Clay B Siegall President and CEO buy | $1.2M 150,000 shares | +29% | - | |
| 50Moderate | Philip Tsai Chief Technology Officer buy | $198k 21,000 shares | - | - | |
| 49Moderate | Robert Lechleider Chief Medical Officer buy | $150k 15,805 shares | - | - | |
| 70Notable | Clay B Siegall President and CEO buy | $962k 100,000 shares | +24% | - |
Transactions
The last 19 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Jack Higgins Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +18,000 | $1.35 | $24k | 78,250 | 27 d ago |
| Sep 11, 2026 | Jack Higgins Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -13,200 | $25.32 | $334k | 65,050 | 27 d ago |
| Sep 11, 2026 | Jack Higgins Chief Scientific Officer | GGift Common Stock10b5-1 | -8,800 | $0.00 | $0 | 56,250 | 27 d ago |
| Sep 11, 2026 | Jack Higgins Chief Scientific Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | +18,000 | $0.00 | $0 | 133,840 | 27 d ago |
| Jun 10, 2025 | Jean Jacques Bienaime director | AGrant or award Director Stock Option (right to buy)derivative | +18,864 | $0.00 | $0 | 18,864 | Jun 12, 2025 |
| Jun 10, 2025 | Isaac Barchas director | AGrant or award Director Stock Option (right to buy)derivative | +18,864 | $0.00 | $0 | 18,864 | Jun 12, 2025 |
| Jun 10, 2025 | James P Boylan director | AGrant or award Director Stock Option (right to buy)derivative | +18,864 | $0.00 | $0 | 18,864 | Jun 12, 2025 |
| Jun 3, 2025 | Jean Jacques Bienaime director | POpen-market purchase Common Stock | +5,000 | $9.38 | $47k | 36,415 | Jun 3, 2025 |
| Mar 27, 2025 | Jack Higgins Chief Scientific Officer | MOption exercise Common Stock | +5,200 | $1.35 | $7,020 | 18,729 | Mar 28, 2025 |
| Mar 27, 2025 | Jack Higgins Chief Scientific Officer | MOption exercise Employee Stock option (right to buy)derivative | -5,200 | $0.00 | $0 | 173,840 | Mar 28, 2025 |
| Mar 26, 2025 | Clay B Siegall President and CEO | POpen-market purchase Common Stock | +137,100 | $7.29 | $999k | 806,736 | Mar 26, 2025 |
| Mar 25, 2025 | Jean Jacques Bienaime director | POpen-market purchase Common Stock | +7,800 | $7.78 | $61k | 31,415 | Mar 26, 2025 |
| Mar 24, 2025 | Jean Jacques Bienaime director | POpen-market purchase Common Stock | +7,000 | $8.21 | $57k | 23,615 | Mar 25, 2025 |
| Mar 24, 2025 | Philip Tsai Chief Technology Officer | POpen-market purchase Common Stock | +12,300 | $8.42 | $104k | 33,300 | Mar 25, 2025 |
| Jan 31, 2025 | Clay B Siegall President and CEO | POpen-market purchase Common Stock | +150,000 | $7.75 | $1.2M | 669,636 | Feb 3, 2025 |
| Nov 21, 2024 | Philip Tsai Chief Technology Officer | POpen-market purchase Common Stock | +21,000 | $9.43 | $198k | 21,000 | Nov 25, 2024 |
| Nov 21, 2024 | Robert Lechleider Chief Medical Officer | POpen-market purchase Common Stock | +15,805 | $9.48 | $150k | 15,805 | Nov 25, 2024 |
| Nov 21, 2024 | Clay B Siegall President and CEO | POpen-market purchase Common Stock | +66,057 | $9.54 | $630k | 485,693 | Nov 25, 2024 |
| Nov 22, 2024 | Clay B Siegall President and CEO | POpen-market purchase Common Stock | +33,943 | $9.78 | $332k | 519,636 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jean Jacques Bienaimedirector
- Isaac Barchasdirector
- James P Boylandirector
- Jack HigginsChief Scientific Officer
- Robert LechleiderChief Medical Officer
- Clay B SiegallPresident and CEO
- Philip TsaiChief Technology Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.